Developing next-generation therapeutics for optimal metabolic health. Currently in "stealth mode".

Independent research consulting services in drug discovery focusing on structure-based design and GPCR pharmacology. I have expertise in applying cryo-electron microscopy, x-ray crystallography, computational chemistry, and data science to drug discovery. My past work has led to a dramatic increase in available GPCR membrane protein structures and the successful discovery of novel marketed and clinical-stage drugs. Specific roles and activities:• Deploying novel methods for expression, purification, crystallization and preparation of homogenous samples for cryo-EM single-particle reconstruction• Data collection and processing strategies for x-ray crystallography and cryo-EM campaigns• Model building and optimization strategies for maximizing impact on ligand design• Hit identification strategies utilizing structure and ligand-based approaches• Strategic leveraging of structural data for hit-to-lead and lead-optimization phases of drug discovery• Data management approaches to facilitate streamlined capture of mission-critical information• Interpretation of in-vitro pharmacology data in the context of structure and ligand-based SAR• Utilizing public and internal data sources to provide unique interpretations

Leveraging state-of-the-art cryo-electron microscopy to fuel structure-based discovery for challenging membrane protein targets.

Leveraging Abilita's innovative membrane protein platform to discover groundbreaking therapeutics.

I am leading a team in the generation and integration of structural information pertaining to GPCRs with various ligands and co-factors bound. This information is used for the discovery and optimization of the next generation of pharmaceutically active compounds. Significantly enhancing the development process.

Developing methodology for membrane protein structural biology and structure based drug design.

Development of platform technology for membrane protein structure based drug design efforts.